The effect of glucagon‐like peptide‐1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trials

Date first appeared online	06/05/2020
DOI	10.1111/dom.14079
Authors	Bain S.
Journal Name	Diabetes, Obesity and Metabolism
Volume

Documents

• 54314VOR.pdf , Book, Released under the terms of a Creative Commons Attribution‐NonCommercial License (CC-BY-NC).